Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with non-small cell lung cancer.
Epidermal growth factor receptor
PANAMutyper®
liquid biopsy
non-small cell lung cancer
plasma
Journal
Journal of cancer research and therapeutics
ISSN: 1998-4138
Titre abrégé: J Cancer Res Ther
Pays: India
ID NLM: 101249598
Informations de publication
Date de publication:
Historique:
entrez:
15
9
2020
pubmed:
16
9
2020
medline:
20
11
2020
Statut:
ppublish
Résumé
Somatic mutations of the gene encoding epidermal growth factor receptor (EGFR) are detected in approximately 30%-50% of patients with non-small cell lung cancers (NSCLC), so detection of EGFR mutation is the pivotal step of treatment in patients with advanced NSCLC. However, difficulty in obtaining sufficient tissue and bias from the heterogeneity of the tumor samples are the major obstacles. Although analyzing EGFR with circulating tumor DNA (ctDNA) in plasma is a breakthrough, accuracy is the problem in variable methods. Peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis (PANAMutyper This study was designed to evaluate PANAMutyper EGFR mutation status detected by PNA clamp with tissue samples and by PANAMutyper The concordance rate of tissue and plasma samples was 91.9% (124/135). The sensitivity, specificity, negative predictive value, and positive predictive value were 64.5%, 100%, 90.4%, and 100%, respectively, according to the tissue samples as a standard. PANAMutyper
Sections du résumé
BACKGROUND
BACKGROUND
Somatic mutations of the gene encoding epidermal growth factor receptor (EGFR) are detected in approximately 30%-50% of patients with non-small cell lung cancers (NSCLC), so detection of EGFR mutation is the pivotal step of treatment in patients with advanced NSCLC. However, difficulty in obtaining sufficient tissue and bias from the heterogeneity of the tumor samples are the major obstacles. Although analyzing EGFR with circulating tumor DNA (ctDNA) in plasma is a breakthrough, accuracy is the problem in variable methods. Peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis (PANAMutyper
AIMS AND OBJECTIVES
OBJECTIVE
This study was designed to evaluate PANAMutyper
MATERIALS AND METHODS
METHODS
EGFR mutation status detected by PNA clamp with tissue samples and by PANAMutyper
RESULTS
RESULTS
The concordance rate of tissue and plasma samples was 91.9% (124/135). The sensitivity, specificity, negative predictive value, and positive predictive value were 64.5%, 100%, 90.4%, and 100%, respectively, according to the tissue samples as a standard. PANAMutyper
Identifiants
pubmed: 32930128
pii: JCanResTher_2020_16_4_843_264700
doi: 10.4103/jcrt.JCRT_515_18
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
843-849Déclaration de conflit d'intérêts
None